Phase | Study type | Agent | Disease | Delivery platform | Animal model | Clinical trial no | Clinical trial title | Status | Publication |
I and II | Immuno-prevention | FSPs: 209 Neoantigens | Lynch Syndrome | Adenovirus and Modified vaccinia Ankara virus | n/a | NCT05078866 | Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients | Not yet recruiting | n/a |
I and II | Immuno-prevention | FSPs: CASP-5 and TGFBR2; TAA: CEA | Lynch Syndrome | Dendritic Cell | n/a | NCT01885702 | Dendritic Cell Vaccination in Patients with Lynch Syndrome or Colorectal Cancer With MSI | Active, not recruiting | 121 |
I and II | Immuno-prevention | FSPs: AIM2, HT001 and TAF1B | Lynch Syndrome | Peptide vaccination | n/a | NCT01461148 | Vaccination Against MSI Colorectal Cancer | Completed | 115 |
Preclinical | Immuno-prevention | Cancer neoantigens | Melanoma, Lymphoma, other | RNA | dogs | n/a | Vaccination Against Canine Cancer | Recruiting | 114 |
Preclinical | Immuno-prevention and chemoprevention | Aspirin, Naproxen; FSPs: Nacad, Xirp1, Maz, Senp6 | Lynch Syndrome | Peptide vaccination | Lynch syndrome mouse model | n/a | Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity with Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model | Completed | 120 |
Preclinical | Immuno-prevention | FSPs: Senp6 | Lynch Syndrome | Dendritic Cell | tumor transplantation mouse model | n/a | On the development of a neoantigen vaccine for the prevention of Lynch Syndrome | Completed | 130 |
Search terms: prevention and Lynch syndrome or frameshift peptides.
45 Finn OJ. The dawn of vaccines for cancer prevention. Nat RevImmunol 2018;18:183–94.